Table 1 Characteristics of each trial included in meta-analysis
Author (year) | Study setting (s) | Trial registration | Anti-TB therapy | Type, dose and route of treatment (intervention) |
|---|---|---|---|---|
Martineau 2011 [21] | UK | NCT00419068 | 2 months HRZE | Vit D3, 2.5 mg,oral |
Daley 2015 [16] | India | NCT00366470 | 2 months HRZE | Vit D3, 2.5 mg,oral |
Farazi 2017 [36] | Iran | IRCT201407029855N5 | 2 months HRZE then 4 months RH | Vit D3,11.2 mg,intramuscular |
Mily 2015 [18] | Bangladesh | NCT01580007 | 2 months HRZE then 4 months RH | Vit D3,0.13 mg and PBA,500 mg,oral |
Nursyam 2006 [37] | Indonesia | NM | 2 months HRZE then 4 months RH | Vit D3, 0.25 mg,oral |
Ralph 2013 [20] | Indonesia | NCT00677339 | 2 months HRZE then 4 months RH | Vit D3,1.25 mg, and L-arginine,6 g,oral |
Salahuddin 2013 [14] | Pakistan | NCT01130311 | 2 months HRZE, then6 months HE | Vit D3,15 mg, intramuscular |
Tukvadze 2015 [39] | Georgia | NCT00918086 | 2 months HRZE then 4 months RH | Vit D3,1.25 mg, oral |
Wejse 2009 [38] | Guinea-Bissau | ISRCTN35212132 | 2 months HRZE, then 6 months HE | Vita D3, 2.5 mg,oral |
Johnson 2003 [40] | Uganda | NM | 2 months HRZE then 4 months RH | rIL-2,11.2 mg,intradermal |
Mayanja-Kizza 2005 [41] | Uganda | NM | 2 months HRZE then 4 months RH | Prednisolone, 2.75 mg,oral |
Pedral-Sampaio 2003 [44] | Brazil | NM | 2 months HRZ then 4 months RH | Rhu-GM-CSF,125 μg, subcutaneous |
Willis 1996 [42] | Ugandan | NM | 2 months HRZ then 4 months RH | Pentoxifylline,1800 mg,oral |
Mahakalkar 2017 [43] | India | not registered | 2 months HRZ then 4 months RH | N-acetylcysteine,600 mg,oral |
Ganmaa 2017 [15] | Mongolia | NCT01657656 | 2 months HRZE | vit D3, 3.5 mg,oral |